Checkmate 012: 1L nivolumab ± ipilimumab:
efficacy by tumor PDL1 expression
•
5 CRs (10%) were achieved in the nivolumab monotherapy cohort (1 in a patient with tumor
PD-L1 expression <1%)
•
6 CRs (8%) were achieved in the nivolumab + ipilimumab cohorts
a
(3 in patients with tumor PD-
L1 expression <1%)
43
21
57
92
23
13
28
50
0
20
40
60
80
100
Nivo 3 Q2W + Ipi 1 Q6/12W
n
52
77
16
19
32
46
12
13
ORR (%)
PD-L1 expression
Overall
<1%
≥1%
≥50%
Hellmann MD Lancet Oncol 2017
